What is it used for?
UNLOXCYT ® is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.UNLOXCYT ® is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- cosibelimabcosibelimab
- Form and strength
- INJECTION, SOLUTION · 300 mg / 5 mLINJECTION, SOLUTION · 300 mg / 5 mL
- Manufacturer / applicant
- SUN PHARMACEUTICAL INDUSTRIES, INC.SUN PHARMACEUTICAL INDUSTRIES, INC.
Injection: 300 mg/5 mL (60 mg/mL), clear to opalescent, colorless to yellow or slightly brown solution in a single-dose vial.Injection: 300 mg/5 mL (60 mg/mL), clear to opalescent, colorless to yellow or slightly brown solution in a single-dose vial.
Safety and clinical review
- Severe and Fatal Immune-Mediated Adverse ReactionsSevere and Fatal Immune-Mediated Adverse Reactions
- Infusion-Related ReactionsInfusion-Related Reactions
- Complications of Allogeneic HSCTComplications of Allogeneic HSCT
- Embryo-Fetal ToxicityEmbryo-Fetal Toxicity
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is UNLOXCYT used for?
UNLOXCYT ® is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.UNLOXCYT ® is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of UNLOXCYT should I ask about?
INJECTION, SOLUTION · 300 mg / 5 mLINJECTION, SOLUTION · 300 mg / 5 mL
Read the primary sourceWhat determines the price of UNLOXCYT?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using UNLOXCYT?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.